scholarly journals Clopidogrel is no better or worse than aspirin when combined with proton pump inhibitors in the prevention of major adverse event. Is the jury out?

2021 ◽  
Vol 36 (7) ◽  
pp. 1733-1734
Author(s):  
Joseph JY Sung
Keyword(s):  
Adverse Event ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Major Adverse Event

scholarly journals Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database

2021 ◽  
Vol 8 ◽  
Author(s):  
Yifan Zeng ◽  
Ying Dai ◽  
Ziye Zhou ◽  
Xuben Yu ◽  
Dawei Shi
Keyword(s):  
Adverse Event ◽  
Adverse Effects ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Case Reports ◽  
Adverse Event Reporting System ◽  
Adverse Event Report ◽  
Event Report ◽  
Hepatocellular Injury ◽  
Suspect Drug

Background and Objectives: Mounting evidence demonstrates that proton pump inhibitors (PPIs) are associated with a number of adverse effects. However, the literatures about hepatotoxicity-related adverse effects (HRAEs) of PPIs are mostly case reports and a few clinical studies.Methods: We evaluated the association between PPIs and HAREs using the reporting odd ratio (ROR) for mining the adverse event report signals in the FDA Adverse Event Reporting System (FAERS) database.Results: There were 23,825 reports of PPIs as primary suspect drug or second suspect drug, of which 3,253 reports were HRAEs. The top five HRAE signals caused by PPIs were hepatitis cholestatic, cholestasis, fulminant hepatitis, subacute hepatic failure, and acute hepatitis. We also summarized the signals of the HRAEs caused by each PPI. The simultaneous signals were cholestasis and hepatitis cholestatic. For the cholestasis signal, esomeprazole showed an ROR of 21.556 (95% CI 17.592–26.413); pantoprazole showed the highest ROR of 22.611 (95% CI 17.794–28.733) in the hepatic cholestatic signal; lansoprazole was the only PPI with expression in the coma hepatic signal, with an ROR of 10.424 (95% CI 3.340–32.532). By analyzing the reports of pantoprazole-induced hepatic encephalopathy, we found that patients aged over 65 years and males reported the highest rate. And from the combination of drugs and indications of drugs, no significant results were obtained.Conclusions: The RORs of signals of “cholestasis” were generally higher than those of “hepatocellular injury.” And the signals about “cholestasis” in HRAE caused by PPIs are more reported.

Inhibitory effect of proton pump inhibitors against chemotaxis of Helicobacter pylori

2001 ◽  
Vol 120 (5) ◽  
pp. A655-A656
Author(s):  
H NAKAMURA ◽  
H YOSHIYAMA ◽  
H YANAI ◽  
M SHIRAL ◽  
T NAKAZAWA ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Inhibitory Effect

Abstract #728: Severe Hypomagnesemia and Breakthrough Seizure with Proton Pump Inhibitors Use

2015 ◽  
Vol 21 ◽  
pp. 139
Author(s):  
Muhammad Mahmood ◽  
Andrew Kinch ◽  
Woodall Brittany ◽  
Ayman Elkadry
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Breakthrough Seizure

Abstract #713 Proton Pump Inhibitors and Hypocalcemia: Does it Really Happen?

2018 ◽  
Vol 24 ◽  
pp. 157-158
Author(s):  
Franco Vallejo Garcia ◽  
Melissa Sum
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump

Erratum: Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI

2009 ◽  
Vol 104 (4) ◽  
pp. 1072-1072
Author(s):  
Joel J Heidelbaugh ◽  
Kathleen L Goldberg ◽  
John M Inadomi
Keyword(s):  
Cost Effectiveness ◽  
Proton Pump Inhibitors ◽  
Proton Pump
Sign in / Sign up

Export Citation Format

Share Document